Repeated Melatonin Supplementation Improves Sleep in Hypertensive Patients Treated with Beta-Blockers: A Randomized Controlled Trial
Year: 2012
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: STUDY OBJECTIVES: In the United States alone, approximately 22 million people take beta-blockers chronically. These medications suppress endogenous nighttime melatonin secretion, which may explain a reported side effect of insomnia. Therefore, we tested whether nightly melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers. DESIGN: Randomized, double-blind, placebo-controlled, parallel-group design. SETTING: Clinical and Translational Research Center at Brigham and Women's Hospital, Boston. PATIENTS: Sixteen hypertensive patients (age 45-64 yr; 9 women) treated with the beta-blockers atenolol or metoprolol. INTERVENTIONS: Two 4-day in-laboratory admissions including polysomnographically recorded sleep. After the baseline assessment during the first admission, patients were randomized to 2.5 mg melatonin or placebo (nightly for 3 weeks), after which sleep was assessed again during the second 4-day admission. Baseline-adjusted values are reported. One patient was removed from analysis because of an unstable dose of prescription medication. MEASUREMENTS AND RESULTS: In comparison with placebo, 3 weeks of melatonin supplementation significantly increased total sleep time (+36 min; P = 0.046), increased sleep efficiency (+7.6%; P = 0.046), and decreased sleep onset latency to Stage 2 (-14 min; P = 0.001) as assessed by polysomnography. Compared with placebo, melatonin significantly increased Stage 2 sleep (+41 min; P = 0.037) but did not significantly change the durations of other sleep stages. The sleep onset latency remained significantly shortened on the night after discontinuation of melatonin administration (-25 min; P = 0.001), suggesting a carryover effect. CONCLUSION: n hypertensive patients treated with beta-blockers, 3 weeks of nightly melatonin supplementation significantly improved sleep quality, without apparent tolerance and without rebound sleep disturbance during withdrawal of melatonin supplementation (in fact, a positive carryover effect was demonstrated). These findings may assist in developing countermeasures against sleep disturbances associated with beta-blocker therapy. CLINICAL TRIAL INFORMATION: his study is registered with ClinicalTrials.gov, identifier: NCT00238108; trial name: Melatonin Supplements for Improving Sleep in Individuals with Hypertension; URL: http://www.clinicaltrials.gov/ct2/show/NCT00238108.
Source: SLEEP
DOI: 10.5665/sleep.2122
Authors: Frank A.J.L. Scheer, Christopher J. Morris, Joanna I. Garcia, Carolina Smales, Erin E. Kelly, Jenny Marks, Atul Malhotra, Steven A. Shea
Language: English
Subfield: Endocrine and Autonomic Systems
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
Funders: National Aeronautics and Space Administration, National Sleep Foundation, Harvard Catalyst, National Space Biomedical Research Institute, National Institutes of Health, National Heart, Lung, and Blood Institute, National Center for Research Resources, National Center for Complementary and Integrative Health
Awards: G1104587562, G1357089762, G2496518617, Chronobiology of cardiovascular and pulmonary disease, G3241421835, Harvard Clinical and Translational Science Center (UL1), Assessment of Upper Airway Mechanics Using Newer EMG Techniques, G3740841103, General Clinical Research Center, Melatonin Supplementation in Hypertensive Patients, New Faculty in Sleep Medicine, G816501378, G8712084307
OpenAlex ID: W2089733557
